What's fueling the biotech engine—2008
- 1 November 2009
- journal article
- Published by Springer Nature in Nature Biotechnology
- Vol. 27 (11) , 987-993
- https://doi.org/10.1038/nbt1109-987
Abstract
Despite the global economic slowdown, biologics managed single-digit growth in 2008, driven mainly by continued high growth in sales of antibodies and insulins. Novel biologics in development look promising, but crowding, pricing and reimbursement are emerging as longer-term concerns.Keywords
This publication has 6 references indexed in Scilit:
- Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label studyDiabetologia, 2009
- Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in SwedenDiabetologia, 2009
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- What's fueling the biotech engine—2007Nature Biotechnology, 2008
- What's fueling the biotech engine?Nature Biotechnology, 2007
- INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATIONRetina, 2006